Effects of E-Tonus in Moderate Parkinson's Disease (ETMOPARK)
A Randomized, Double-blind, Sham-controlled, Crossover, Pilot Clinical Investigation, Evaluating the Short-term Effects of E-Tonus, a Wearable Electromagnetic Device, on Motor Symptoms in Adult Participants With Moderate Parkinson's Disease
The goal of this clinical trial is to evaluate the short-term effect of E-Tonus, a wrist-worn device that gives off a low-intensity pulsed electromagnetic field, on functional mobility in adults with moderate Parkinson's disease. It will also learn about the short-term safety profile of E-Tonus.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Unzutreffend
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Senior Clinical Project Manager
- Telefonnummer: +33624358886
- E-Mail: clinical@brainandmind.fr
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Adults aged 50-75 years;
- Parkinson's disease (MDS diagnostic criteria)Hoehn & Yahr stage II to II.5 confirmed in the ON medication state;
- At least one of the following MDS-UPDRS criteria must be met, reflecting the presence of clinically meaningful gait or balance impairment but still able to walk unaided:
- MDS-UPDRS Gait (item 3.10) score = 2, OR
- Freezing of gait (item 3.11) score ranging from 1 to 2, OR
- Postural instability (item 3.12) score ranging from 1 to 2, OR
- Walking & Balance (item 2.12) score = 2, OR
- Freezing (item 2.13) score ranging from 1 to 2;
- Stable dopaminergic therapy ≥4 weeks;
- Predictable ON-state duration ≥2 consecutive hours.
Exclusion Criteria:
- Severe axial motor impairment (pre-specified items rated 3 or 4) or investigator-judged fall/safety risk;
- Pregnancy;
- Electromagnetic hypersensitivity;
- Postural hypotension, musculoskeletal, or vestibular disorders affecting balance;
- Uncontrolled cardiac, pulmonary, major neurological, or metabolic disease;
- Cognitive impairment (MoCA ≤22);
- Implanted active medical device (e.g., DBS, pacemaker) or metal implant/tattoo at the wrist application site;
- History of radial nerve injury on the device-bearing arm;
- Legally protected vulnerable adults.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Unterstützende Pflege
- Zuteilung: Zufällig
- Interventionsmodell: Crossover-Aufgabe
- Maskierung: Vervierfachen
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Active E-Tonus
Participants wear E-Tonus on the wrist in the active condition, emitting low-frequency, low-intensity pulsed electromagnetic field stimulation, for approximately 30 minutes. In this crossover study, all participants receive both the active and sham conditions during a single study visit, in a randomized order, separated by a 30-minute washout period. Assessments are performed in the ON medication state. |
Personal, portable, wrist-worn, non-invasive Class IIa electromagnetic stimulation device manufactured by A.F. Genese. It emits a low-frequency, low-intensity pulsed electromagnetic field with a controlled pulse width, delivering peripheral transcutaneous stimulation at the wrist. Used once, for approximately 30 minutes, during a single study visit, in addition to the participant's usual Parkinson's disease medication. The same wrist-worn device in a sham configuration that emits no electromagnetic field. It is visually and physically indistinguishable from the active device, so that participants and investigators remain blinded. Used once, for approximately 30 minutes, during a single study visit. |
|
Schein-Komparator: Sham E-Tonus
Participants wear E-Tonus on the wrist in the sham condition, with no stimulation emitted, for approximately 30 minutes. The sham device is visually and physically indistinguishable from the active device. In this crossover study, all participants receive both the active and sham conditions during a single study visit, in a randomized order, separated by a 30-minute washout period. Assessments are performed in the ON medication state. |
Personal, portable, wrist-worn, non-invasive Class IIa electromagnetic stimulation device manufactured by A.F. Genese. It emits a low-frequency, low-intensity pulsed electromagnetic field with a controlled pulse width, delivering peripheral transcutaneous stimulation at the wrist. Used once, for approximately 30 minutes, during a single study visit, in addition to the participant's usual Parkinson's disease medication. The same wrist-worn device in a sham configuration that emits no electromagnetic field. It is visually and physically indistinguishable from the active device, so that participants and investigators remain blinded. Used once, for approximately 30 minutes, during a single study visit. |
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Change in instrumented Timed Up-and-Go (iTUG) 7-meter total task time: active vs. sham E-Tonus
Zeitfenster: Baseline (before each device condition) and end-of-period (after approximately 30 minutes of device use), for each of the 2 device conditions within a single study visit (Day 1)
|
The iTUG test measures the time (in seconds) a participant needs to stand up from a chair, walk 7 meters, turn around, walk back and sit down again, from the start of the sit-to-stand transition to the end of the stand-to-sit transition. It is instrumented with an accelerometer. Two trials are performed at each time point and averaged. For each device condition (active and sham), the change from baseline to end-of-period is calculated. The outcome is the difference between active and sham conditions in this change. A greater reduction in time indicates better functional mobility. |
Baseline (before each device condition) and end-of-period (after approximately 30 minutes of device use), for each of the 2 device conditions within a single study visit (Day 1)
|
|
Incidence, severity, seriousness and relatedness of adverse events (AEs) and adverse device effects (ADEs)
Zeitfenster: From the start of the first device application (Day 1) through 48 hours after the last device application
|
Number of participants with adverse events and adverse device effects, described by severity (mild, moderate, severe), seriousness (serious or non-serious) and relationship to the device as assessed by the investigator, by device condition (active and sham). |
From the start of the first device application (Day 1) through 48 hours after the last device application
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: David DEVOS, Professor Neurologist, Service de Neurologie B : Neurologie vasculaire CHU de Lille - Hôpital Roger Salengro rue Emile Laine 59000 LILLE
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- BM2601-AFGE01
- IDRCB N° 2026-A01795-46 (Andere Kennung: ANSM (French National Agency for Medicines and Health Products Safety))
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
There is no plan to share individual participant data. This is a small pilot investigation (40 participants), and the data are collected under French and European data protection regulations (GDPR), with participant consent limited to the purposes of this study. Aggregate results will be made available through scientific publication.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .